A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
Price : $35 *
At a glance
- Drugs Paclitaxel trevatide (Primary) ; Trastuzumab
- Indications Brain metastases; Breast cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 26 Apr 2013 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.
- 01 Dec 2012 Status changed from recruiting to discontinued.